Small bowel adenocarcinoma (SBA) is a rare tumor with an unfavorable prognosis, and due to its rarity, few studies on its treatment are available. Chemotherapy remains the standard of treatment in advanced disease. Recently immunotherapy has demonstrated to be a valid therapeutic option for many solid tumors. We reviewed the data published in literature to understand the impact of immunotherapy in this cancer.
Keywords: MSI; PDL-1; Small bowel cancer; TMB; duodenal cancer; ileum tumor; jejunal cancer; metastatic cancer; predictive markers.